Faculty: B. Douglas Smith, MD
Last Modified: October 21, 2012
Chronic myeloid leukemia (CML) is a myeloproliferative disorder of the blood stem cells that accounts for approximately 15% of all adult leukemias. Recent changes to standard therapy, combined with the development of novel CML agents, have led to challenges with regard to escalation and transition of therapy and management of treatment-related side effects. This continuing education activity will improve the ability of oncologists and other clinicians to treat and manage CML through application of contemporary CML guidelines and utilization of novel CML therapies.
Nov 6, 2013 - Ponatinib is active in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, according to a study published online Nov. 1 in the New England Journal of Medicine.
May 9, 2013
Jul 30, 2010